LOGO
LOGO

CAI On Watch: FDA Clearance, Peer-Reviewed Validation, And Lock-Up Countdown In Focus

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
cai 01102025 lt

AI TechBio company Caris Life Sciences Inc. (CAI) remains active on watchlists following its recent public debut and a series of clinical and regulatory milestones.

The company priced its initial public offering on June 17, 2025, at $21.00 per share, above the initial range, and began trading on the Nasdaq Global Select Market under the ticker "CAI" on June 18, 2025.

The company raised $159.4 million in net proceeds from the pre-IPO financing on April 1, 2025, and $519.5 million in net proceeds from the IPO in June 2025.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.